Streetbeat News

Regulatory

ACXP

Acurx Pharmaceuticals has announced the efficacy results from the Phase 2 trial of Ibezapolstat for C. Difficile infection, with a 96% clinical cure rate in patients after 10 days of oral treatment. The trial met its primary objective of assessing the primary efficacy endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:44 am

CMP

Compass Minerals has announced the suspension of further investment in its planned lithium project until it has clarity on the evolving regulatory climate in Utah.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:29 am

SUPN

Supernus Pharmaceuticals has announced that the US FDA has acknowledged the resubmission of the New Drug Application (NDA) for the continuous treatment of motor fluctuations in Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:27 am

VGK

The Eurozone Manufacturing Purchasing Managers' Index (PMI) for October was reported at 43.1, lower than the estimated 43.4.

Portfolio Pulse from Charles Gross

November 02, 2023 | 9:05 am

VGK

The Eurozone Manufacturing Purchasing Managers Index (PMI) for October is reported at 43.1, slightly above the estimated 43.0 but below the prior figure of 43.4.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 9:04 am

VGK

The Manufacturing Purchasing Managers' Index (PMI) for the Eurozone in October was reported at 43.1, significantly higher than the estimated 3.4.

Portfolio Pulse from Charles Gross

November 02, 2023 | 9:03 am

EWG

Germany's Manufacturing Purchasing Managers Index (PMI) for October was reported at 40.8, slightly above the estimated 40.7 and significantly higher than the previous month's 39.6.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:55 am

EWQ

The France Manufacturing Purchasing Managers Index (PMI) for October is reported at 42.8, slightly above the estimated 42.6 but lower than the prior figure of 44.2.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:51 am

MOLN

Molecular Partners has released initial data from its ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS. The preliminary data indicates an acceptable safety profile with no dose-limiting toxicity or severe adverse reactions. Five patients across three dosing regimens have been treated as of 20 July 2023.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 7:00 am

PNW

Pinnacle West Capital's subsidiary, APS, has filed the 2023 APS Integrated Resource Plan (IRP) at the Arizona Corporation Commission. The IRP provides a 15-year outlook on electricity needs of APS customers and necessary investments to meet those needs, considering the unprecedented growth of people and businesses moving to Arizona.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 6:47 am